规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
靶点 |
IL-1β; IL-6; p38 MAPK
|
---|---|
体外研究 (In Vitro) |
Semapimod tetraHClide (CNI-1493) 显着降低中性粒细胞浸润、巨噬细胞中的 p38-MAPK 磷酸化、白细胞介素 6、单核细胞趋化蛋白 1 和细胞间粘附分子 1 促炎基因表达。赛马莫德四盐酸盐完全消除了肌层中一氧化氮的合成。通过影响 TLR 伴侣 gp96,semapimod tetraHClide 使 TLR 信号传导脱敏。 gp96 的 ATP 结合和 ATP 酶活性在体外被塞马莫德四盐酸盐抑制 (IC50≈0.2-0.4 μM)。通过影响 TLR 伴侣 gp96,semapimod tetraHClide 使 TLR 信号传导脱敏。
|
体内研究 (In Vivo) |
在肥胖 Zucker (OZ) 大鼠中,塞马莫德四盐酸盐 (CNI-1493)(5 mg/kg;腹腔注射;每日一次,持续 2 周)可改善内皮功能障碍。在 OZ 大鼠中,semapimod tetraHClide 逆转 AM 对 akt 磷酸化和 cGMP 合成的影响。
|
参考文献 |
|
分子式 |
C34H52N18O2
|
---|---|
分子量 |
744.9
|
精确质量 |
744.45206
|
元素分析 |
C, 54.82; H, 7.04; N, 33.85; O, 4.30
|
CAS号 |
164301-51-3
|
相关CAS号 |
Semapimod;352513-83-8
|
外观&性状 |
white solid powder
|
SMILES |
C/C(=N\N=C(N)N)/C1=CC(=CC(=C1)NC(=O)CCCCCCCCC(=O)NC2=CC(=CC(=C2)/C(=N/N=C(N)N)/C)/C(=N/N=C(N)N)/C)/C(=N/N=C(N)N)/C.Cl.Cl.Cl.Cl
|
InChi Key |
MAHASPGBAIQZLY-RTQZJKMDSA-N
|
InChi Code |
InChI=1S/C34H52N18O2.4ClH/c1-19(45-49-31(35)36)23-13-24(20(2)46-50-32(37)38)16-27(15-23)43-29(53)11-9-7-5-6-8-10-12-30(54)44-28-17-25(21(3)47-51-33(39)40)14-26(18-28)22(4)48-52-34(41)42;;;;/h13-18H,5-12H2,1-4H3,(H,43,53)(H,44,54)(H4,35,36,49)(H4,37,38,50)(H4,39,40,51)(H4,41,42,52);4*1H/b45-19+,46-20+,47-21+,48-22+;;;;
|
化学名 |
N,N'-bis[3,5-bis[(E)-N-(diaminomethylideneamino)-C-methylcarbonimidoyl]phenyl]decanediamide;tetrahydrochloride
|
别名 |
Semapimod HCl; CNI-1493; CNI1493; CNI1493; AXD-455; AXD455; AXD 455; AIDS121302; AIDS-121302
|
HS Tariff Code |
2934.99.9001
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
H2O: ~2.17 mg/mL (~2.4 mM)
|
---|---|
溶解度 (体内) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 请根据您的实验动物和给药方式选择适当的溶解配方/方案: 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 1.3425 mL | 6.7123 mL | 13.4246 mL | |
5 mM | 0.2685 mL | 1.3425 mL | 2.6849 mL | |
10 mM | 0.1342 mL | 0.6712 mL | 1.3425 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
Measurement of jejunal circular smooth muscle contractility. Spontaneous and bethanechol-induced muscle contractility from controls and placebo or semapimod i.v.–treated IM mice. Gastroenterology . 2009 Feb;136(2):619-29. td> |
Effect of semapimod on GIT (A–D) and colonic transit (E). GIT was measured as the percent of nonabsorbable fluorescein-labeled dextran in 15 gastrointestinal segments—stomach (Sto), small intestine (SI 1–9), cecum (Cec), and colon (Co)—90 minutes after oral ingestion. Gastroenterology . 2009 Feb;136(2):619-29. td> |
Effect of semapimod on intestinal wound healing. Gastroenterology . 2009 Feb;136(2):619-29. td> |
Effects of Semapimod on proinflammatory responses in IEC-6 cells. J Immunol . 2016 Jun 15;196(12):5130-7. td> |
Semapimod blocks activation of NF-κB by a group of TLR ligands. J Immunol . 2016 Jun 15;196(12):5130-7. td> |
Semapimod desensitizes responses to LPS. J Immunol . 2016 Jun 15;196(12):5130-7. td> |